

REFERENCES

- [0110] 1. Arnon, S. S., et al., 2001. Botulinum toxin as a biological weapon. *J. Am. Med. Assoc.* 285:1059-1070.
- [0111] 2. Schiavo, G., et al., *Physiol. Rev.* 80:717-766.
- [0112] 3. Simpson, L. L. 2004. Identification of the major steps in botulinum toxin action, *Ann. Rev. Pharmacol. Toxicol.* 44:167-193.
- [0113] 4. Ahmed, S. A. and L. A. Smith. 2000. Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active. *J. Prot. Chem.* 19:475-487.
- [0114] 5. Gilsdorf, J., N. Gul, and L. A. Smith. 2006. Expression, purification, and characterization of *Clostridium botulinum* type B light chain. *Protein Expr. Purif.* 46:256-267.
- [0115] 6. Cherington, M. 2004. Botulism: update and review. *Semin. Neurol.* 24:155-163.
- [0116] 7. Foster, K. A., P. Hambleton, and C. C. Shone (ed.). 2007. *Treatments From Toxins*. CRC Press, New York, NY.
- [0117] 8. Turton, K., J. A. Chaddock, and K. R. Acharya. 2002. Botulinum and tetanus neurotoxins: structure, function, and therapeutic utility. *Trends Biochem. Sci.* 27:552-558.
- [0118] 9. Ansiaux, R., C. et al., 2006. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. *Clin. Cancer Res.* 12:1276-1283.
- [0119] 10. Bade, S., et al., 2004. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurons via unfolded translocation intermediates. *J. Neurochem.* 91:1461-1472.
- [0120] 11. Foran, P. 2007. Use of neurotoxins as drug delivery systems, p. 213-253. In K. A. Foster, P. Hambleton, and C. C. Shone (ed.), *Treatments From Toxins*. CRC Press, New York, NY.
- [0121] 12. Goodnough, M. C., et al., 2002. Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. *FEBS Lett.* 513:163-168.
- [0122] 13. Zdanovskaia, M. V., et al., 2000. Recombinant derivatives of clostridial neurotoxins as delivery vehicles for proteins and small organic molecules. *J. Protein Chem.* 19:699-707.
- [0123] 14. Wein, L. M., and Y. Liu. 2005. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. *Proc. Natl. Acad. Sci. U. S. A.* 102:9984-9989.
- [0124] 15. Keller, J. E., et al., 2004. Uptake of botulinum neurotoxin into cultured neurons. *Biochemistry.* 43:526-532.
- [0125] 16. Burnett, J. C., et al., 2003. Novel small molecule inhibitors of botulinum neurotoxin protease activity. *Biochem. Biophys. Res. Comm.* 310:85-94.
- [0126] 17. Burnett, J. C., et al., 2007. Inhibition of Metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. *J. Biol. Chem.* 282:5004-5014.
- [0127] 18. Burnett, J. C., et al., 2005. Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. *Bioorg. Med. Chem.* 13:333-341.
- [0128] 19. Merino, I., et al., 2006. Bis-imidazoles as molecular probes for peripheral sites of the zinc endopeptidase of botulinum neurotoxin serotype A. *Bioorg. Med. Chem.* 14:3583-3591.
- [0129] 20. Park, J. G., et al., 2006. Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. *Bioorg. Med. Chem.* 14:395-408.
- [0130] 21. Schmidt, J. J. and K. A. Foster. 2007. Inhibitors of clostridial neurotoxin protease activities, p. 107-138. In K. A. Foster, P. Hambleton, and C. C. Shone (ed.), *Treatments From Toxins*. CRC Press, New York, N.Y.
- [0131] 22. Schmidt, J. J. and R. G. Stafford. 2005. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. *Biochemistry* 44: 4067-4073.
- [0132] 23. Schmidt, J. J. and R. G. Stafford. 2002. A high-affinity competitive inhibitor of type A botulinum neurotoxin metalloprotease activity. *FEBS Lett.* 532:423-426.
- [0133] 24. Schmidt, J. J. and K. A. Bostian. 1997. Endoprotease activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. *J. Prot. Chem.* 16:19-26.
- [0134] 25. Schmidt, J. J., and R. G. Stafford. 2003. Fluorogenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. *Appl. Environ. Microbiol.* 69:297-303.
- [0135] 26. Li, L., et al., 2000. Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain. *Biochemistry* 39:2399-2405.
- [0136] 27. Boldt, G. E., et al., 2006. Synthesis, characterization, and development of a high-throughput methodology for the discovery of botulinum neurotoxin A inhibitors. *J. Comb. Chem.* 8:513-521.
- [0137] 28. Breidenbach, M. A., and A. T. Brunger. 2004. Substrate recognition strategy for botulinum neurotoxin serotype A. *Nature* 432:925-929.
- [0138] 29. Bagramyan, K., et al., 2008. Attomolar Detection of Botulinum Toxin Type A in Complex Biological Matrices. *PLoS ONE* 3(4): e2041. doi:10.1371/journal.pone.0002041.
- [0139] 30. Kistner, A. and Habermann, E. 1992. *Naunyn Schmiedebergs Arch Pharmacol.* 338:99-106.
- [0140] 31. Barr, J. R., et al., 2005. Botulinum Neurotoxin Detection and Differentiation by Mass Spectrometry. *Emerging Infectious Diseases* 11(10): 1578-1583.
- [0141] 32. Dong, M. et al., 2006. *Science*. 312(5773):593-596.
- [0142] All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.